Advertisement
Sam Owusu-Akyaw, President and Chief Executive Officer of Osteotech,stated, "We are very pleased to renew our relationship with the Republic ofBulgaria and the EATA. Through the tissue recovery efforts of bothorganizations over the past five years, Osteotech has been able to use itsprocessing and product technologies to bring safe and clinically effectiveOsteoBiologic products to the European market for use by surgeons to alleviatepain, promote biologic healing and restore function."
Advertisement
Dr. Roman A. Hitchev, President and Chief Medical Officer of TBOsteocentre Bulgaria EAD, an indirect wholly-owned subsidiary of Osteotech,commented, "We have had an excellent working relationship with the EATA overthe last five years and together have established a successful tissue recoverysystem in the Republic of Bulgaria. We look forward to continuing ouroutstanding relationship with the EATA and, working with the EATA, tosuccessfully integrate the Bulgarian tissue recovery and transplantationsystem into the tissue exchange system of the European Union."
Dr. Galina V. Balabanova, M.D., Executive Director of the EATA, remarked,"Osteotech and Osteocentre Bulgaria have been excellent partners andsupporters of tissue banking in Bulgaria. They have a rich tradition intechnological advancement and quality. Osteotech is also a key financialsupporter of the collaboration we have with the Scoliosis Research Society,which allows us to provide pediatric spinal deformity surgery for childrenwithout healthcare insurance coverage."
The EATA, a public non-profit foundation authorized under the BulgarianTransplant Law of 2007 and organized under the Bulgarian Public FoundationsLaw of 2001, is responsible for funding healthcare projects in Bulgaria forthe public benefit, tissue transplantation, international patient referralservices and pediatric spinal deformity surgery for children withouthealthcare insurance coverage. The EATA also provides financial management andfundraising to hospitals and providers participating in the Bulgarian nationaldonor recovery network.
Osteotech, Inc., headquartered in Eatontown, New Jersey, is a globalleader in providing OsteoBiologic solutions for regenerative medicine tosupport surgeons and their patients in the repair of the musculoskeletalsystem through the development of innovative therapy-driven products thatalleviate pain, promote biologic healing and restore function. For furtherinformation regarding Osteotech, this press release or the conference call,please go to Osteotech's website at http://www.osteotech.com.
Certain statements made throughout this press release that are nothistorical facts contain forward-looking statements (as such are defined inthe Private Securities Litigation Reform Act of 1995) regarding the Company'sfuture plans, objectives and expected performance. Any such forward-lookingstatements are based on assumptions that the Company believes are reasonable,but are subject to a wide range of risks and uncertainties and, therefore,there can be no assurance that actual results may not differ materially fromthose expressed or implied by such forward-looking statements. Factors thatcould cause actual results to differ materiall
